Efficacy of molecular-targeted medicine for cancers with driver oncogenes, such as HER-2 amplification in breast cancer, EGFR mutation and ALK-rearrangement in NSCLC, and BRAF mutation in malignant melanoma, is found to be very high. Here, BRAF is linked to non-small cell lung carcinoma.